Viral Therapy for Cancer
Trial Summary
What is the purpose of this trial?
This research is being done because these viruses have been shown to shrink tumours in animals and human tumour samples by selectively killing cancer cells and creating an immune response to the tumour antigen contained in the viruses. This effect has been shown to increase when the AdMA3 virus is given first. It is not clear if this treatment will offer better results than standard treatment.
Research Team
Derek Jonker
Principal Investigator
Ottawa Hospital Research Institute
Eligibility Criteria
Adults with certain advanced solid tumors expressing MAGE-A3, who've had at least one standard treatment. They must have measurable disease and be in good physical condition (ECOG 0 or 1). Excluded are those with active infections, other cancers needing treatment, significant medical issues, brain metastases requiring steroids, or pregnant/breastfeeding individuals.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- AdMA3 (Cancer Vaccine)
- MG1MA3 (Virus Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
Dr. Janet Dancey
Canadian Cancer Trials Group
Chief Medical Officer since 2014
MD, FRCPC
Susan Marlin
Canadian Cancer Trials Group
Chief Executive Officer since 2012
BSc (Hons) from Dalhousie University, MSc in Community Health and Epidemiology from Queen’s University
Ottawa Hospital Research Institute
Collaborator
Dr. Kathleen Gartke
Ottawa Hospital Research Institute
Chief Medical Officer
MD, University of Ottawa
Dr. Rebecca Auer
Ottawa Hospital Research Institute
Chief Executive Officer
MD, Memorial Sloan-Kettering Cancer Centre